David Rimm, MD, PhD | Authors


Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer

January 03, 2020

David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.